Exosomes & Microbiome in Cosmetics: Evidence Grades and Claim Boundaries (2025)

Exosomes and the microbiome are two pillars of next-gen K-beauty, but their regulatory weight moved in opposite directions. Korea expanded ‘exosome’ to a prohibited cosmetic advertising expression in 2025 and bans human-derived cells and tissues as ingredients. The microbiome, by contrast, is settling into a postbiotic-led ‘barrier and soothing’ concept. Here is how the two ingredients map by evidence grade — and which claims you can versus cannot make — from a product-planning and export view.

1. Where the two ingredients stand now

Exosomes are nano-sized vesicles secreted by cells, and K-beauty often places them in ampoule, cream, and skin-booster concepts. In Korea, however, the 2025 expansion of ‘exosome’ as a prohibited ad expression means human-derived exosomes are tightly limited in both ingredient and wording; direct claims like ‘stem-cell regeneration effect’ are off-limits. What matters is less the raw material than its origin, purity, safety dossier, and finished-product human testing.

Microbiome cosmetics rarely add live bacteria; they more often use prebiotics, ferment lysates, and postbiotics. Paired with sensitive-skin, barrier-care, and low-irritation categories, it is a concept buyers grasp easily.

2. Reading them by evidence grade

The grades below are not legal classes — they are a practical yardstick for planners judging the level of evidence.

Ingredient group	Evidence level	Planning read	Claims to watch
Exosome materials	C–B	supplier and cell-assay data, some finished-product human testing	regeneration, wound healing, stem-cell therapy effect
Postbiotics	B–C	ferment-lysate / lactobacillus-derived hydration & barrier support	treating skin flora, immune-disease improvement
Prebiotics	C	hydration & barrier concepts mindful of the skin environment	claiming growth of specific beneficial bacteria

In practice, ‘the ingredient is good’ matters less than ‘did a 2–4 week finished-product human test confirm hydration, skin barrier, redness, and sensitivity measures.’

3. Korea's exosome regulatory points (2025 update)

First, the core fact: in Korea, human-derived cells, tissues, culture media, and placenta-derived substances are prohibited cosmetic ingredients. So an ‘exosome extracted from human cells’ cannot be used as a cosmetic ingredient, and most products on the market use plant- or microbe-derived ‘exosome-like vesicles.’

On top of that, in 2025 the MFDS expanded expressions such as ‘exosome,’ ‘microneedle,’ and ‘hospital-exclusive’ to prohibited cosmetic ad wording. So even with a plant-derived ingredient, advertising the product as an ‘exosome cosmetic’ has become difficult. Exosome is also not a recognized functional-cosmetic ingredient, so whitening, wrinkle-care, or UV claims must go through the notified/reviewed functional-ingredient system.

Suppliers should provide at minimum the INCI name, origin (non-human, e.g. plant or microbial), manufacturing process, sterility and microbial testing, residue control, heavy-metal testing, and stability data. The takeaway: in the Korean market, lean on proven supporting actives and finished-product test data rather than on the word ‘exosome.’

4. The limits of microbiome claims

Acceptable wording stays in the cosmetic range — ‘a formula mindful of the skin microbiome,’ ‘supports skin barrier and hydration,’ ‘sensitive-skin suitability tested.’ By contrast, ‘improves eczema,’ ‘kills acne bacteria,’ ‘treats skin immunity,’ or ‘suppresses harmful bacteria’ can read as drug claims.

5. OEM/ODM & export planning checklist

Before ordering OEM/ODM, check the documents before the ingredient name: the spec sheet, COA, MSDS, allergen / animal-origin / human-origin status, preservation system, and a stability test plan are essential. For export, ingredient naming, new-ingredient determination, and claim rules differ across the EU, US, China, and ASEAN. China is tightening efficacy substantiation and ingredient-safety dossiers, while the US may read disease-treatment or structure/function wording as a drug claim.

For an indie brand, position exosomes as a ‘premium anti-aging concept’ and the microbiome as a ‘sensitive barrier-care concept’ — but keep the scientific wording narrow and aligned with finished-product test results.

Sources

• ChemLinked — Global Regulations on Exosomes in Cosmetic Products
• MFDS (Korea) — Cosmetic Labeling & Advertising Guideline
• Cosmetics & Toiletries — Microbiome Claims: Should Pre-, Pro- and Postbiotic Skin Care Be Regulated?